# Core Laboratories Inc.: financial statements, quarterly

CLB · NYSE · CIK 1958086 · [Energy](/sectors/energy.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/clb.md) · [Financials](/companies/clb/financials.md) · [Filings](/companies/clb/filings.md) · [Insiders](/companies/clb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/clb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [125](/filings/0000950170-24-117122.md) | [128 d](/filings/0001193125-26-118177.md) | [130](/filings/0000950170-25-058900.md) | [131](/filings/0000950170-25-098473.md) | [134](/filings/0001193125-25-248736.md) | [129 d](/filings/0001193125-26-118177.md) | [124](/filings/0001193125-26-198109.md) | [130](/filings/0001193125-26-326345.md) | [135](/filings/0001193125-25-248736.md) | [138 d](/filings/0001193125-26-118177.md) | [122](/filings/0001193125-26-198109.md) | [125](/filings/0001193125-26-326345.md) |
| Cost of revenue | $m | not reported | not reported | [105](/filings/0000950170-25-058900.md) | [103](/filings/0000950170-25-098473.md) | [107](/filings/0001193125-25-248736.md) | [106 d](/filings/0001193125-26-118177.md) | [99.5](/filings/0001193125-26-198109.md) | [104](/filings/0001193125-26-326345.md) | [105](/filings/0001193125-25-248736.md) | [110 d](/filings/0001193125-26-118177.md) | [102](/filings/0001193125-26-198109.md) | [101](/filings/0001193125-26-326345.md) |
| Operating income | $m | [14.7](/filings/0000950170-24-117122.md) | [14.6 d](/filings/0001193125-26-118177.md) | [8.6](/filings/0000950170-25-058900.md) | [16.0](/filings/0000950170-25-098473.md) | [19.8](/filings/0001193125-25-248736.md) | [14.2 d](/filings/0001193125-26-118177.md) | [4.4](/filings/0001193125-26-198109.md) | [15.3](/filings/0001193125-26-326345.md) | [20.9](/filings/0001193125-25-248736.md) | [15.8 d](/filings/0001193125-26-118177.md) | [1.9](/filings/0001193125-26-198109.md) | [9.2](/filings/0001193125-26-326345.md) |
| Interest expense | $m | [3.1](/filings/0000950170-24-117122.md) | [3.6 d](/filings/0001193125-26-118177.md) | [3.4](/filings/0000950170-25-058900.md) | [3.2](/filings/0000950170-25-098473.md) | [3.1](/filings/0001193125-25-248736.md) | [2.6 d](/filings/0001193125-26-118177.md) | [2.6](/filings/0001193125-26-198109.md) | [2.7](/filings/0001193125-26-326345.md) | [2.7](/filings/0001193125-25-248736.md) | [2.6 d](/filings/0001193125-26-118177.md) | [2.9](/filings/0001193125-26-198109.md) | [2.8](/filings/0001193125-26-326345.md) |
| Income tax | $m | [2.3](/filings/0000950170-24-117122.md) | [8.5 d](/filings/0001193125-26-118177.md) | [1.7](/filings/0000950170-25-058900.md) | [3.6](/filings/0000950170-25-098473.md) | [4.7](/filings/0001193125-25-248736.md) | [4.1 d](/filings/0001193125-26-118177.md) | [1.7](/filings/0001193125-26-198109.md) | [1.9](/filings/0001193125-26-326345.md) | [3.8](/filings/0001193125-25-248736.md) | [8.1 d](/filings/0001193125-26-118177.md) | [(0.3)](/filings/0001193125-26-198109.md) | [0.5](/filings/0001193125-26-326345.md) |
| Net income | $m | [9.3](/filings/0000950170-24-117122.md) | [2.2 d](/filings/0001193125-26-118177.md) | [3.2](/filings/0000950170-25-058900.md) | [9.0](/filings/0000950170-25-098473.md) | [11.7](/filings/0001193125-25-248736.md) | [7.4 d](/filings/0001193125-26-118177.md) | [(0.2)](/filings/0001193125-26-198109.md) | [10.6](/filings/0001193125-26-326345.md) | [14.2](/filings/0001193125-25-248736.md) | [4.9 d](/filings/0001193125-26-118177.md) | [(0.8)](/filings/0001193125-26-198109.md) | [6.0](/filings/0001193125-26-326345.md) |
| Diluted EPS | $ per share | [0.19](/filings/0000950170-24-117122.md) | not reported | [0.07](/filings/0000950170-25-058900.md) | [0.19](/filings/0000950170-25-098473.md) | [0.25](/filings/0001193125-25-248736.md) | not reported | [0.00](/filings/0001193125-26-198109.md) | [0.22](/filings/0001193125-26-326345.md) | [0.30](/filings/0001193125-25-248736.md) | not reported | [(0.02)](/filings/0001193125-26-198109.md) | [0.13](/filings/0001193125-26-326345.md) |
| Basic EPS | $ per share | [0.20](/filings/0000950170-24-117122.md) | not reported | [0.07](/filings/0000950170-25-058900.md) | [0.19](/filings/0000950170-25-098473.md) | [0.25](/filings/0001193125-25-248736.md) | not reported | [0.00](/filings/0001193125-26-198109.md) | [0.23](/filings/0001193125-26-326345.md) | [0.31](/filings/0001193125-25-248736.md) | not reported | [(0.02)](/filings/0001193125-26-198109.md) | [0.13](/filings/0001193125-26-326345.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [16.6](/filings/0000950170-23-058206.md) | [15.1](/filings/0000950170-25-019072.md) | [14.9](/filings/0000950170-24-048414.md) | [17.7](/filings/0000950170-24-086610.md) | [21.5](/filings/0000950170-24-117122.md) | [19.2](/filings/0001193125-26-118177.md) | [22.1](/filings/0000950170-25-058900.md) | [31.2](/filings/0000950170-25-098473.md) | [25.6](/filings/0001193125-25-248736.md) | [22.7](/filings/0001193125-26-326345.md) | [22.8](/filings/0001193125-26-198109.md) | [22.7](/filings/0001193125-26-326345.md) |
| Current assets | $m | [229](/filings/0000950170-23-058206.md) | [223](/filings/0000950170-25-019072.md) | [229](/filings/0000950170-24-048414.md) | [234](/filings/0000950170-24-086610.md) | [235](/filings/0000950170-24-117122.md) | [221](/filings/0001193125-26-118177.md) | [229](/filings/0000950170-25-058900.md) | [238](/filings/0000950170-25-098473.md) | [227](/filings/0001193125-25-248736.md) | [215](/filings/0001193125-26-326345.md) | [214](/filings/0001193125-26-198109.md) | [214](/filings/0001193125-26-326345.md) |
| Total assets | $m | [592](/filings/0000950170-24-117122.md) | [586](/filings/0001193125-26-118177.md) | [598](/filings/0000950170-25-098473.md) | [598](/filings/0000950170-25-098473.md) | [600](/filings/0001193125-25-248736.md) | [585](/filings/0001193125-26-118177.md) | [586](/filings/0001193125-26-198109.md) | [597](/filings/0001193125-26-326345.md) | [591](/filings/0001193125-25-248736.md) | [584](/filings/0001193125-26-326345.md) | [588](/filings/0001193125-26-198109.md) | [587](/filings/0001193125-26-326345.md) |
| Current liabilities | $m | [84.3](/filings/0000950170-23-058206.md) | [88.1](/filings/0000950170-25-019072.md) | [85.5](/filings/0000950170-24-048414.md) | [97.6](/filings/0000950170-24-086610.md) | [94.9](/filings/0000950170-24-117122.md) | [102](/filings/0001193125-26-118177.md) | [104](/filings/0000950170-25-058900.md) | [105](/filings/0000950170-25-098473.md) | [95.7](/filings/0001193125-25-248736.md) | [106](/filings/0001193125-26-326345.md) | [105](/filings/0001193125-26-198109.md) | [101](/filings/0001193125-26-326345.md) |
| Long-term debt | $m | [178](/filings/0000950170-23-058206.md) | [163](/filings/0000950170-25-019072.md) | [160](/filings/0000950170-24-048414.md) | [148](/filings/0000950170-24-086610.md) | [140](/filings/0000950170-24-117122.md) | [126](/filings/0001193125-26-118177.md) | [124](/filings/0000950170-25-058900.md) | [125](/filings/0000950170-25-098473.md) | [114](/filings/0001193125-25-248736.md) | [110](/filings/0001193125-26-326345.md) | [114](/filings/0001193125-26-198109.md) | [114](/filings/0001193125-26-326345.md) |
| Shareholders' equity | $m | [225](/filings/0000950170-23-058206.md) | [225](/filings/0000950170-25-019072.md) | [232](/filings/0000950170-24-048414.md) | [240](/filings/0000950170-24-086610.md) | [251](/filings/0000950170-24-117122.md) | [247](/filings/0001193125-26-118177.md) | [253](/filings/0000950170-25-058900.md) | [261](/filings/0000950170-25-098473.md) | [271](/filings/0001193125-25-248736.md) | [266](/filings/0001193125-26-326345.md) | [269](/filings/0001193125-26-198109.md) | [273](/filings/0001193125-26-326345.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(0.2) d](/filings/0000950170-24-117122.md) | [19.4 d](/filings/0001193125-26-118177.md) | [5.5](/filings/0000950170-25-058900.md) | [17.1 d](/filings/0000950170-25-098473.md) | [13.1 d](/filings/0001193125-25-248736.md) | [20.6 d](/filings/0001193125-26-118177.md) | [6.7](/filings/0001193125-26-198109.md) | [13.9 d](/filings/0001193125-26-326345.md) | [8.5 d](/filings/0001193125-25-248736.md) | [7.9 d](/filings/0001193125-26-118177.md) | [4.0](/filings/0001193125-26-198109.md) | [7.8 d](/filings/0001193125-26-326345.md) |
| Capital expenditure | $m | [3.5](/filings/0000950170-23-058206.md) | [2.7 d](/filings/0001193125-26-118177.md) | [3.1](/filings/0000950170-25-058900.md) | [2.9 d](/filings/0000950170-25-098473.md) | [2.7 d](/filings/0001193125-25-248736.md) | [3.2 d](/filings/0001193125-26-118177.md) | [2.8](/filings/0001193125-26-198109.md) | [3.5 d](/filings/0001193125-26-326345.md) | [2.0 d](/filings/0001193125-25-248736.md) | [2.9 d](/filings/0001193125-26-118177.md) | [3.4](/filings/0001193125-26-198109.md) | [4.7 d](/filings/0001193125-26-326345.md) |
| Dividends paid | $m | [0.5 d](/filings/0000950170-24-117122.md) | [0.5 d](/filings/0001193125-26-118177.md) | [0.5](/filings/0000950170-25-058900.md) | [0.5 d](/filings/0000950170-25-098473.md) | [0.5 d](/filings/0001193125-25-248736.md) | [0.5 d](/filings/0001193125-26-118177.md) | [0.5](/filings/0001193125-26-198109.md) | [0.5 d](/filings/0001193125-26-326345.md) | [0.5 d](/filings/0001193125-25-248736.md) | [0.5 d](/filings/0001193125-26-118177.md) | [0.5](/filings/0001193125-26-198109.md) | [0.5 d](/filings/0001193125-26-326345.md) |
| Share repurchases | $m | [0.2 d](/filings/0000950170-24-117122.md) | [1.8 d](/filings/0001193125-26-118177.md) | [0.0](/filings/0000950170-25-058900.md) | [0.2 d](/filings/0000950170-25-098473.md) | [0.2 d](/filings/0001193125-25-248736.md) | [4.9 d](/filings/0001193125-26-118177.md) | [2.0](/filings/0001193125-26-198109.md) | [2.7 d](/filings/0001193125-26-326345.md) | [5.0 d](/filings/0001193125-25-248736.md) | [2.7 d](/filings/0001193125-26-118177.md) | [4.0](/filings/0001193125-26-198109.md) | [2.7 d](/filings/0001193125-26-326345.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2022-09-30) | period not labelled (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [47.0](/filings/0000950170-23-058206.md) | [47.5](/filings/0000950170-24-048414.md) | [47.5](/filings/0000950170-24-086610.md) | [47.6](/filings/0000950170-24-117122.md) | [47.7](/filings/0000950170-25-058900.md) | [47.7](/filings/0000950170-25-098473.md) | [47.8](/filings/0001193125-25-248736.md) | [46.8](/filings/0001193125-26-198109.md) | [47.4](/filings/0001193125-26-326345.md) | [47.1](/filings/0001193125-25-248736.md) | [46.1](/filings/0001193125-26-198109.md) | [46.9](/filings/0001193125-26-326345.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 45,884,542 at 2026-07-24, from the cover of the [10-Q filed 2026-07-30](/filings/0001193125-26-326345.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.